Stock comparison
Johnson & Johnson
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
JNJ
Johnson & Johnson
Market cap
$545.74B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.32B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | JNJ | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 54C | 69B | LMAT |
| Benjamin Graham | 60C | 81A | LMAT |
| Philip Fisher | 53C | 73B | LMAT |
| Peter Lynch | 57C | 59C | LMAT |
| Joel Greenblatt | 39D | 48D | LMAT |
| Charlie Munger | 53C | 60C | LMAT |
| Terry Smith | 46D | 61C | LMAT |
Side-by-side metrics
| Metric | JNJ | LMAT |
|---|---|---|
| Market cap | $545.74B | $2.32B |
| P/E (TTM) | 26.3x | 37.1x |
| EV/EBIT | 21.2x | 36.6x |
| ROIC (TTM) | 13.6% | 9.43% |
| Gross margin | 69.12% | 72.39% |
| Net margin | 21.83% | 24.35% |
| Revenue CAGR 5y | 4.58% | 12.75% |
| EPS CAGR 5y | 8.6% | 19.04% |
| Debt / Equity | 0.2x | 0.5x |
| Dividend yield | 2.29% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
JNJ leads on
- Market cap$545.74Bvs $2.32B+100%
- Dividend yield2.29%vs 0.84%+64%
- Debt / Equity0.2xvs 0.5x+54%
- EV/EBIT21.2xvs 36.6x+42%
LMAT leads on
- Revenue CAGR 5y12.75%vs 4.58%+64%
- EPS CAGR 5y19.04%vs 8.6%+55%
- Net margin24.35%vs 21.83%+10%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.